Quantitative integrative survival prediction in multiple myeloma patients treated with bortezomib-based induction, high-dose therapy and autologous stem cell transplantation

Purpose - Given the high heterogeneity in survival for patients with multiple myeloma, it would be clinically useful to quantitatively predict the individual survival instead of attributing patients to two to four risk groups as in current models, for example, revised International Staging System (R...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Hummel, Manuela (VerfasserIn) , Hielscher, Thomas (VerfasserIn) , Emde-Rajaratnam, Martina (VerfasserIn) , Salwender, Hans (VerfasserIn) , Beck, Susanne (VerfasserIn) , Scheid, Christoph (VerfasserIn) , Bertsch, Uta (VerfasserIn) , Goldschmidt, Hartmut (VerfasserIn) , Jauch, Anna (VerfasserIn) , Moreaux, Jérôme (VerfasserIn) , Seckinger, Anja (VerfasserIn) , Hose, Dirk (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: July 10, 2024
In: JCO precision oncology
Year: 2024, Jahrgang: 8, Pages: 1-12
ISSN:2473-4284
DOI:10.1200/PO.23.00613
Online-Zugang:Verlag, kostenfrei, Volltext: https://doi.org/10.1200/PO.23.00613
Verlag, kostenfrei, Volltext: https://ascopubs.org/doi/10.1200/PO.23.00613
Volltext
Verfasserangaben:Manuela Hummel; Thomas Hielscher; Martina Emde-Rajaratnam; Hans Salwender; Susanne Beck; Christof Scheid; Uta Bertsch; Hartmut Goldschmidt; Anna Jauch; Jérôme Moreaux; Anja Seckinger; and Dirk Hose

MARC

LEADER 00000caa a2200000 c 4500
001 1898041288
003 DE-627
005 20241205160903.0
007 cr uuu---uuuuu
008 240807s2024 xx |||||o 00| ||eng c
024 7 |a 10.1200/PO.23.00613  |2 doi 
035 |a (DE-627)1898041288 
035 |a (DE-599)KXP1898041288 
035 |a (OCoLC)1475306082 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Hummel, Manuela  |d 1980-  |e VerfasserIn  |0 (DE-588)13827651X  |0 (DE-627)601096592  |0 (DE-576)306984172  |4 aut 
245 1 0 |a Quantitative integrative survival prediction in multiple myeloma patients treated with bortezomib-based induction, high-dose therapy and autologous stem cell transplantation  |c Manuela Hummel; Thomas Hielscher; Martina Emde-Rajaratnam; Hans Salwender; Susanne Beck; Christof Scheid; Uta Bertsch; Hartmut Goldschmidt; Anna Jauch; Jérôme Moreaux; Anja Seckinger; and Dirk Hose 
264 1 |c July 10, 2024 
300 |b Illustrationen 
300 |a 12 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 07.08.2024 
520 |a Purpose - Given the high heterogeneity in survival for patients with multiple myeloma, it would be clinically useful to quantitatively predict the individual survival instead of attributing patients to two to four risk groups as in current models, for example, revised International Staging System (R-ISS), R2-ISS, or Mayo-2022-score. - Patients and Methods - Our aim was to develop a quantitative prediction tool for individual patient's 3-/5-year overall survival (OS) probability. We integrated established clinical and molecular risk factors into a comprehensive prognostic model and evaluated and validated its risk discrimination capabilities versus R-ISS, R2-ISS, and Mayo-2022-score. - Results - A nomogram for estimating OS probabilities was built on the basis of a Cox regression model. It allows one to translate the individual risk profile of a patient into 3-/5-year OS probabilities by attributing points to each prognostic factor and summing up all points. The nomogram was externally validated regarding discrimination and calibration. There was no obvious bias or overfitting of the prognostic index on the validation cohort. Resampling-based and external evaluation showed good calibration. The c-index of the model was similar on the training (0.76) and validation cohort (0.75) and significantly higher than for the R-ISS (P < .001) or R2-ISS (P < .01). - Conclusion - In summary, we developed and validated individual quantitative nomogram-based OS prediction. Continuous risk assessment integrating molecular prognostic factors is superior to R-ISS, R2-ISS, or Mayo-2022-score alone. 
700 1 |a Hielscher, Thomas  |e VerfasserIn  |0 (DE-588)1159594791  |0 (DE-627)1022977768  |0 (DE-576)50506068X  |4 aut 
700 1 |a Emde-Rajaratnam, Martina  |d 1988-  |e VerfasserIn  |0 (DE-588)116096193X  |0 (DE-627)1024350673  |0 (DE-576)506290433  |4 aut 
700 1 |a Salwender, Hans  |e VerfasserIn  |0 (DE-588)1114928666  |0 (DE-627)869399993  |0 (DE-576)477578233  |4 aut 
700 1 |a Beck, Susanne  |d 1985-  |e VerfasserIn  |0 (DE-588)1164102362  |0 (DE-627)1028488866  |0 (DE-576)508378915  |4 aut 
700 1 |a Scheid, Christoph  |e VerfasserIn  |0 (DE-588)1075475244  |0 (DE-627)833299670  |0 (DE-576)443494495  |4 aut 
700 1 |a Bertsch, Uta  |e VerfasserIn  |0 (DE-588)1026849861  |0 (DE-627)727494163  |0 (DE-576)372176224  |4 aut 
700 1 |a Goldschmidt, Hartmut  |d 1956-  |e VerfasserIn  |0 (DE-588)102258023X  |0 (DE-627)717003809  |0 (DE-576)365637386  |4 aut 
700 1 |a Jauch, Anna  |d 1959-  |e VerfasserIn  |0 (DE-588)1025525140  |0 (DE-627)722525362  |0 (DE-576)168357496  |4 aut 
700 1 |a Moreaux, Jérôme  |e VerfasserIn  |0 (DE-588)1158626851  |0 (DE-627)1020610077  |0 (DE-576)504256734  |4 aut 
700 1 |a Seckinger, Anja  |d 1980-  |e VerfasserIn  |0 (DE-588)134177371  |0 (DE-627)562118225  |0 (DE-576)278603734  |4 aut 
700 1 |a Hose, Dirk  |d 1969-  |e VerfasserIn  |0 (DE-588)139824995  |0 (DE-627)613790308  |0 (DE-576)313431698  |4 aut 
773 0 8 |i Enthalten in  |t JCO precision oncology  |d Alexandria, VA : American Society of Clinical Oncology, 2017  |g 8(2024), Artikel-ID e2300613, Seite 1-12  |h Online-Ressource  |w (DE-627)1067396667  |w (DE-600)2964799-X  |w (DE-576)518266486  |x 2473-4284  |7 nnas  |a Quantitative integrative survival prediction in multiple myeloma patients treated with bortezomib-based induction, high-dose therapy and autologous stem cell transplantation 
773 1 8 |g volume:8  |g year:2024  |g elocationid:e2300613  |g pages:1-12  |g extent:12  |a Quantitative integrative survival prediction in multiple myeloma patients treated with bortezomib-based induction, high-dose therapy and autologous stem cell transplantation 
856 4 0 |u https://doi.org/10.1200/PO.23.00613  |x Verlag  |x Resolving-System  |z kostenfrei  |3 Volltext 
856 4 0 |u https://ascopubs.org/doi/10.1200/PO.23.00613  |x Verlag  |z kostenfrei  |3 Volltext 
951 |a AR 
992 |a 20240807 
993 |a Article 
994 |a 2024 
998 |g 139824995  |a Hose, Dirk  |m 139824995:Hose, Dirk  |d 50000  |e 50000PH139824995  |k 0/50000/  |p 12  |y j 
998 |g 134177371  |a Seckinger, Anja  |m 134177371:Seckinger, Anja  |d 50000  |e 50000PS134177371  |k 0/50000/  |p 11 
998 |g 1025525140  |a Jauch, Anna  |m 1025525140:Jauch, Anna  |d 910000  |d 911500  |d 50000  |e 910000PJ1025525140  |e 911500PJ1025525140  |e 50000PJ1025525140  |k 0/910000/  |k 1/910000/911500/  |k 0/50000/  |p 9 
998 |g 102258023X  |a Goldschmidt, Hartmut  |m 102258023X:Goldschmidt, Hartmut  |d 910000  |d 910100  |e 910000PG102258023X  |e 910100PG102258023X  |k 0/910000/  |k 1/910000/910100/  |p 8 
998 |g 1026849861  |a Bertsch, Uta  |m 1026849861:Bertsch, Uta  |d 910000  |d 910100  |e 910000PB1026849861  |e 910100PB1026849861  |k 0/910000/  |k 1/910000/910100/  |p 7 
998 |g 1164102362  |a Beck, Susanne  |m 1164102362:Beck, Susanne  |d 910000  |d 912000  |e 910000PB1164102362  |e 912000PB1164102362  |k 0/910000/  |k 1/910000/912000/  |p 5 
998 |g 116096193X  |a Emde-Rajaratnam, Martina  |m 116096193X:Emde-Rajaratnam, Martina  |d 50000  |e 50000PE116096193X  |k 0/50000/  |p 3 
998 |g 1159594791  |a Hielscher, Thomas  |m 1159594791:Hielscher, Thomas  |d 50000  |e 50000PH1159594791  |k 0/50000/  |p 2 
998 |g 13827651X  |a Hummel, Manuela  |m 13827651X:Hummel, Manuela  |d 140000  |e 140000PH13827651X  |k 0/140000/  |p 1  |x j 
999 |a KXP-PPN1898041288  |e 4563502375 
BIB |a Y 
SER |a journal 
JSO |a {"language":["eng"],"person":[{"role":"aut","given":"Manuela","family":"Hummel","display":"Hummel, Manuela"},{"family":"Hielscher","display":"Hielscher, Thomas","given":"Thomas","role":"aut"},{"role":"aut","given":"Martina","family":"Emde-Rajaratnam","display":"Emde-Rajaratnam, Martina"},{"given":"Hans","role":"aut","family":"Salwender","display":"Salwender, Hans"},{"display":"Beck, Susanne","family":"Beck","given":"Susanne","role":"aut"},{"given":"Christoph","role":"aut","family":"Scheid","display":"Scheid, Christoph"},{"display":"Bertsch, Uta","family":"Bertsch","role":"aut","given":"Uta"},{"given":"Hartmut","role":"aut","display":"Goldschmidt, Hartmut","family":"Goldschmidt"},{"display":"Jauch, Anna","family":"Jauch","role":"aut","given":"Anna"},{"role":"aut","given":"Jérôme","display":"Moreaux, Jérôme","family":"Moreaux"},{"given":"Anja","role":"aut","display":"Seckinger, Anja","family":"Seckinger"},{"given":"Dirk","role":"aut","display":"Hose, Dirk","family":"Hose"}],"id":{"eki":["1898041288"],"doi":["10.1200/PO.23.00613"]},"relHost":[{"language":["eng"],"titleAlt":[{"title":"JCO PO"}],"part":{"pages":"1-12","year":"2024","volume":"8","text":"8(2024), Artikel-ID e2300613, Seite 1-12","extent":"12"},"title":[{"subtitle":"an American Society of Clinical Oncology journal","title_sort":"JCO precision oncology","title":"JCO precision oncology"}],"pubHistory":["Volume 1 (2017)-"],"origin":[{"dateIssuedDisp":"2017-","dateIssuedKey":"2017","publisher":"American Society of Clinical Oncology","publisherPlace":"Alexandria, VA"}],"note":["Gesehen am 06.07.21"],"disp":"Quantitative integrative survival prediction in multiple myeloma patients treated with bortezomib-based induction, high-dose therapy and autologous stem cell transplantationJCO precision oncology","type":{"media":"Online-Ressource","bibl":"periodical"},"physDesc":[{"extent":"Online-Ressource"}],"recId":"1067396667","id":{"issn":["2473-4284"],"zdb":["2964799-X"],"eki":["1067396667"]}}],"recId":"1898041288","name":{"displayForm":["Manuela Hummel; Thomas Hielscher; Martina Emde-Rajaratnam; Hans Salwender; Susanne Beck; Christof Scheid; Uta Bertsch; Hartmut Goldschmidt; Anna Jauch; Jérôme Moreaux; Anja Seckinger; and Dirk Hose"]},"physDesc":[{"extent":"12 S.","noteIll":"Illustrationen"}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"note":["Gesehen am 07.08.2024"],"origin":[{"dateIssuedKey":"2024","dateIssuedDisp":"July 10, 2024"}],"title":[{"title_sort":"Quantitative integrative survival prediction in multiple myeloma patients treated with bortezomib-based induction, high-dose therapy and autologous stem cell transplantation","title":"Quantitative integrative survival prediction in multiple myeloma patients treated with bortezomib-based induction, high-dose therapy and autologous stem cell transplantation"}]} 
SRT |a HUMMELMANUQUANTITATI1020